Drug intelligence / Profile preview

PTX-301

Development stage: Preclinical
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

PTX-301 is an mRNA-based vaccine candidate developed by Providence Therapeutics specifically for animal health applications. It is designed to target avian influenza virus antigens to provide protection against Highly Pathogenic Influenza (HPI) in veterinary settings. As an mRNA vaccine, it functions by delivering genetic instructions to animal cells to produce specific viral antigens, thereby stimulating a protective immune response. The program is currently in the Proof-of-Concept stage of development, representing an expansion of Providence's mRNA platform into the prevention of infectious diseases in livestock and poultry.

Targets

H1 HA (Influenza A hemagglutinin H1)

Beyond the preview

Go deeper on PTX-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-301.

Explore the full profile